ArticleBioprocess and biosystems engineering2025
Investigation of in vitro delivery conditions for self-amplifying mRNA.
Article in Bioprocess and biosystems engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Self-amplifying mRNA (SAM) shows promise for vaccines and gene therapy because of its self-replicating ability. However, current studies lack sufficient information for systematic parameter optimization and differentiation from conventional non-replicating mRNA (NRM). Therefore, the transfection efficiency of NRM and SAM platforms was evaluated by comparing delivery vectors and optimizing parameters for the SAM protocol. SAM and NRM showed similar transfection preferences, but their efficiencies differed. Optimized SAM transfection parameters were then established, including dose and incubation time. In this study, an in vitro multi-parameter delivery system for SAM was constructed, providing valuable insights into SAM transfection and its distinction from regular mRNA. This study contributes an experimental basis for the rational screening of nucleic acid drug carriers and the establishment of SAM multi-parameter evaluation criteria, and also lays an important foundation for optimizing low-dose immunization strategies and their clinical application translation.
Indexed as
Identifiers
40762708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.